Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations

AAPS PharmSciTech

Volumn 16, Issue 5, 2015, Pages 1091-1100

  Liu, Yajun ^a   Salituro, Gino M ^a   Lee, Keun joong ^a   Bak, Annette ^a   Leung, Dennis H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

anti solvent precipitation; controlled release; formulation; nanoparticles; solid lipid

Indexed keywords

LIPID; SOLID LIPID NANOPARTICLE; TORCETRAPIB; DELAYED RELEASE FORMULATION; DRUG CARRIER; HYPOCHOLESTEROLEMIC AGENT; NANOPARTICLE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COLLOID; CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; RAT; SOLID; TEMPERATURE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; ORAL DRUG ADMINISTRATION; SOLUBILITY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; LIPIDS; MALE; MODELS, BIOLOGICAL; NANOPARTICLES; PARTICLE SIZE; QUINOLINES; RATS, WISTAR; SOLUBILITY; TEMPERATURE;

EID: 84944515060     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-015-0299-8     Document Type: Article

References (34)

1. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29(3–4):278–87.
2. Chen XQ, Gudmundsson OS, Hageman MJ. Application of lipid-based formulations in drug discovery. J Med Chem. Sep 27;55(18):7945-56.
3. Porter CJ, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673–91.
4. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.
5. Puri A, Loomis K, Smith B, Lee JH, Yavlovich A, Heldman E, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–80.
6. Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv. 2005;2(1):75–87.
7. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114(1):53–9.
8. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317(1):82–9.
9. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release. 2009;133(3):238–44.
10. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77.
11. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96.
12. Wang S, Chen T, Chen R, Hu Y, Chen M, Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm. Jul 1;430(1-2):238-46.
13. Pardeike J, Weber S, Haber T, Wagner J, Zarfl HP, Plank H, et al. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. Oct 31;419(1-2):329-38.
14. Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. Jan 18;42(1-2):11-8.
15. Bose S, Du Y, Takhistov P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. Int J Pharm. Jan 30;441(1-2):56-66.
16. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin a in solid lipid nanoparticles (SLN). Int J Pharm. 2002;241(2):341–4.
17. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337(1–2):299–306.
18. Passerini N, Qi S, Albertini B, Grassi M, Rodriguez L, Craig DQ. Solid lipid microparticles produced by spray congealing: influence of the atomizer on microparticle characteristics and mathematical modeling of the drug release. J Pharm Sci. Feb;99(2):916-31.
19. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298(4):1015–9.
20. Shah N, Iyer RM, Mair HJ, Choi DS, Tian H, Diodone R, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci. Mar;102(3):967-81.
21. Miller MA, DiNunzio J, Matteucci ME, Ludher BS, Williams RO, Johnston KP. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm. May;38(5):557-70.
22. Schubert MA, Muller-Goymann CC. Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm. 2003;55(1):125–31.
23. Perlman ME, Murdande SB, Gumkowski MJ, Shah TS, Rodricks CM, Thornton-Manning J, et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib. Int J Pharm. 2008;351(1–2):15–22.
24. Dennis Leung TDN, Timothy A. Rhodes, Elizabeth Kwong, inventor Nano-suspension process. 2013.
25. D'Addio SM, Prud'homme RK. Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. May 30;63(6):417-26.
26. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm. Aug 30;415(1-2):232-43.
27. Pathak P, Nagarsenker M. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech. 2009;10(3):985–92.
28. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharmaceutics. 2008;5(6):1003–19.
29. Freitas C, Muller RH. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm. 1999;47(2):125–32.
30. Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 1987;5(1):23–36.
31. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17(4):397–404.
32. Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JA. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008;5(6):1003–19.
33. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50(1):47–60.
34. Ambike AA, Mahadik KR, Paradkar A. Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in vitro and in vivo evaluations. Pharm Res. 2005;22(6):990–8.